Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis Republished

Background: Induction treatment of mild-to-moderate Crohn's disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease. Data sources: We identified randomized controlled trials from existing Cochrane reviews and an updated literature search in Medline, EMBASE, and CENTRAL to November 2015. Study selection: We included randomized controlled trials (n = 22) in adult patients with Crohn's disease that compared budesonide, sulfasalazine, mesalamine, or corticosteroids with placebo or each other, for the induction of remission (8–17 wks). Mesalamine (above and below 2.4 g/d) and budesonide (above and below 6 mg/d) were stratified into low and high doses. Data extraction: Our primary outcome was remission, defined as a Crohn's Disease Activity Index score <150. A Bayesian random-effects network meta-analysis was performed on the proportion in remission. Data synthesis: Corticosteroids (odds ratio [OR] = 3.64; 95% credible interval [CrI]: 2.16–6.19), high-dose budesonide (OR = 2.99; 95% CrI: 1.83–4.90), and high-dose mesalamine (OR = 1.87; 95% CrI: 1.14–3.15) were superior to placebo. Corticosteroids were similar to high-dose budesonide (OR = 1.21; 95% CrI: 0.79–1.89), but more effective than high-dose mesalamine (OR = 1.95; 95% CrI: 1.14–3.25). Sulfasalazine was not significantly superior to any therapy including placebo. Limitations: Randomized controlled trials that use a strict definition of induction of remission and disease severity at enrollment to assess effectiveness in treating mild-to-moderate Crohn's disease are limited. Conclusions: Corticosteroids and high-dose budesonide were effective treatments for inducing remission in mild-to-moderate Crohn's disease. High-dose mesalamine maybe an option among patients preferring to avoid steroids.

[1]  G. Kaplan,et al.  The global burden of IBD: from 2015 to 2025 , 2015, Nature Reviews Gastroenterology &Hepatology.

[2]  S. Bonovas,et al.  Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[3]  G. Kaplan,et al.  The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti‐TNF use: a time‐trend study , 2014, Alimentary pharmacology & therapeutics.

[4]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  T. Hibi,et al.  Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. , 2013, Journal of Crohn's & colitis.

[6]  A. Bitton,et al.  Inflammatory bowel disease: a Canadian burden of illness review. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[7]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[8]  M. Sculpher,et al.  Bayesian methods for evidence synthesis in cost-effectiveness analysis , 2012, PharmacoEconomics.

[9]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[10]  C. Glasmacher,et al.  Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. , 2011, Gastroenterology.

[11]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.

[12]  S. Hanauer,et al.  Aminosalicylates for induction of remission or response in Crohn's disease. , 2010, The Cochrane database of systematic reviews.

[13]  E. Benchimol,et al.  Budesonide for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[14]  C. Porter,et al.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. , 2008, Gastroenterology.

[15]  A. Griffiths,et al.  Traditional corticosteroids for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[16]  R. Gearry,et al.  5‐Aminosalicylic acid (mesalazine) use in Crohn's disease: A survey of the opinions and practice of Australian gastroenterologists , 2007, Inflammatory bowel diseases.

[17]  A. Tursi,et al.  Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[18]  A. Otley,et al.  Budesonide for induction of remission in Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[19]  H. Herfarth,et al.  Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization , 2004, International Journal of Colorectal Disease.

[20]  S. Hanauer,et al.  Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States , 2002, American Journal of Gastroenterology.

[21]  S. Hanauer,et al.  Management of Crohn's disease in adults , 2001, American Journal of Gastroenterology.

[22]  G. Porro,et al.  Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. , 1999, Gastroenterology.

[23]  A. Lavy,et al.  Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. , 1998, Gastroenterology.

[24]  D. Jewell,et al.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. , 1998, The New England journal of medicine.

[25]  D. Jewell,et al.  A Comparison of Budesonide and Mesalamine for Active Crohn's Disease , 1998 .

[26]  M. Campieri,et al.  Oral budesonide is as effective as oral prednisolone in active Crohn’s disease , 1997, Gut.

[27]  J. Schölmerich,et al.  Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. , 1996, European journal of gastroenterology & hepatology.

[28]  W. Fischbach,et al.  Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. , 1995, Zeitschrift fur Gastroenterologie.

[29]  H. Verspaget,et al.  Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease , 1995, Alimentary pharmacology & therapeutics.

[30]  A. Zinsmeister,et al.  A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. , 1994, Journal of clinical gastroenterology.

[31]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[32]  G. Greenberg,et al.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.

[33]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[34]  I. Beck,et al.  Oral 5-ASA Versus Prednisone in Short Term Treatment of Crohn's Disease: A Multicentre Controlled Trial , 1990 .

[35]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[36]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.